TECELRA ® launch 2025 YTD metrics: 28 ATCs available; 21 patients aphresed; and 14 doses invoiced $4.0 million Tecelra net sales in Q1 2025 Instituting 2025 Tecelra full year sales guidance of $35-$45 million Lete-cel on track to initiate rolling BLA submission late 2025; approval anticipated in 2026 Adaptimmune had Total Liquidity 1 of $60 million as of March 31, 2025; call at 8 a.m. EDT today Philadelphia, Pennsylvania and... Read More

Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - May 7, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, will report financial results and provide business updates for the first quarter of 2025, before the US markets open on Tuesday, May 13, 2025. Following the announcement, the Company will host a live webcast at 8:00... Read More

TECELRA ® launch momentum accelerating – 10 patients apheresed in Q1 2025 and 3 in 2024; 20 ATCs available; all manufacturing and supply goals achieved Lete-cel on track to initiate rolling BLA submission late 2025; approval anticipated 2026 Corporate restructure completed in February 2025 and implementing additional cost reduction for PRAME and CD70 programs At the end of 2024, Adaptimmune had Total Liquidity 1 of $152... Read More

Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - March 12, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, will report financial results and provide business updates for the fourth quarter and full year ended December 31, 2024, before the US markets open on Thursday, March 20, 2025. Following the announcement, the... Read More

Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - January 30, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to redefine the treatment of solid tumor cancers with cell therapy, today announced that management will participate in the Guggenheim Securities SMID Cap Biotech Conference this February. Guggenheim Securities SMID Cap Biotech Conference, New York, NY Fireside chat with... Read More

The Company will present at the Annual J.P. Morgan Healthcare Conference, providing business updates on its sarcoma franchise and other cell therapy pipeline assets Adaptimmune Allo-T program to be featured at the Biotech ShowCase (TM) and the Wuxi Global Forum 2025 Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - January 13, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to... Read More

Helen Tayton-Martin, Ph.D., M.B.A, Adaptimmune Co-Founder and Chief Business & Strategy Officer, will step down from the Company March 31, 2025 Gavin Wood, Chief Financial Officer, will step down from the Company May 31, 2025 Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - December 19, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to redefine the treatment of solid tumor... Read More

Dosing marks a milestone for first engineered cell therapy approved in the U.S. for a solid tumor cancer, synovial sarcoma Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - December 2, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to redefine the treatment of solid tumor cancers with cell therapy, today announced that the first patient has been treated with TECELRA ®... Read More

Tecelra® launch on track with 9 Authorized Treatment Centers available to initiate patient treatment journey, and the first patient apheresed in Q3; expect first commercial revenues in Q4 and the number of treated patients to accelerate throughout 2025 Lete-cel IGNYTE-ESO pivotal trial primary analysis reports 42% overall response rate in synovial sarcoma and myxoid/round cell liposarcoma (MRCLS); full data at CTOS... Read More

42% of people with advanced or metastatic synovial sarcoma or MRCLS had clinical responses with lete-cel Results include six complete responses (6/64); twenty-one partial responses (21/64) Data to be presented at Connective Tissue Oncology Society 2024 Annual Meeting Company plans to initiate a rolling BLA submission for lete-cel for the treatment of advanced or metastatic synovial sarcoma and MRCLS by end of 2025 Company to... Read More

Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - November 5, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to redefine the treatment of solid tumor cancers with cell therapy, today announced presence and presentations at key scientific and medical conferences in November and December. Society for Immunotherapy of Cancer (SITC) 39 th annual meeting, November 6-10, Houston, TX... Read More

Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - October 31, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, will report financial results and provide business updates for the third quarter ended September 30, 2024, after the US markets close on Wednesday, November 13, 2024. Following the announcement, the Company will... Read More

Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - August 28, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to redefine the treatment of solid tumor cancers with cell therapy, today announced that management will participate in two investment bank conferences this September. Wells Fargo Healthcare Conference, Boston, MA Fireside chat: Wednesday September 4, 2024, at 4:30 PM EDT.... Read More

Adaptimmune received U.S. FDA accelerated approval of Tecelra® (afami-cel), the first approved engineered cell therapy for a solid tumor Patients can begin treatment journey; biomarker testing available; Adaptimmune systems ready to receive orders At the end of Q2, Adaptimmune had Total Liquidity [1] of $214.8 million Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - August 12, 2024) - Adaptimmune... Read More

Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - August 5, 2024) - Adaptimmune Therapeutics plc (Nasdaq: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, will report financial results and provide business updates for the second quarter ended June 30, 2024, before the US markets open on Monday, August 12, 2024. Following the announcement, the Company will host a live... Read More

Approved for advanced MAGE-A4+synovial sarcoma in adults with certain HLA types who have received prior chemotherapy TECELRA is the first new treatment option for people with synovial sarcoma in more than a decade Adaptimmune to hold webcast at https://www.gowebcasting.com/13428 on August 2, at 8:00 a.m. EDT PHILADELPHIA &... Read More

Overall response rate of 40% consistent across sarcoma indications; median duration of response ~11 months with patients still in response at time of analysis Interim analysis data reinforces the potential of lete-cel to bolster Adaptimmune's sarcoma franchise by expanding addressable sarcoma patient population Full results from the pivotal IGNYTE-ESO trial are expected in late 2024 Philadelphia, Pennsylvania and Oxford,... Read More

Adaptimmune and Galapagos to conduct clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel (next-generation MAGE-A4 TCR T-cell therapy) produced on Galapagos' decentralized manufacturing platform in patients with head & neck cancer Uza-cel has shown encouraging results in head & neck cancer with partial responses in four out of five patients to date in a Phase 1 trial using Adaptimmune's centralized... Read More

Afami-cel commercial and regulatory update presented at Company's Investor Day (replay HERE ); FDA review and inspections progressing with PDUFA date of August 4th, 2024 Commercial and manufacturing infrastructure in place to support afami-cel commercial launch upon approval Data from SPEARHEAD-1 pivotal trial with afami-cel published in The Lancet; data from a planned interim analysis of pivotal lete-cel IGNYTE-ESO trial to... Read More

First tranche of $25 million available upon closing; the Company will be eligible to draw an additional $25 million subject to afami-cel approval Philadelphia, Pennsylvania and Oxford, United Kindgom--(Newsfile Corp. - May 15, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, today announced that it has entered into a $125 million five-year, term... Read More

Philadelphia, Pennsylvania and Oxford, United Kindgom--(Newsfile Corp. - May 1, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, will report financial results and provide business updates for the first quarter ended March 31, 2024, before the US markets open on Wednesday, May 15, 2024. Following the announcement, the Company will host a live... Read More

Company remains focused on launching afami-cel later this year with a PDUFA date of August 4 th and developing its broader sarcoma franchise Update on afami-cel launch plans to be provided at the April 18 th Investor Day Philadelphia, Pennsylvania and Oxford, United Kindgom--(Newsfile Corp. - April 12, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell... Read More

Philadelphia, Pennsylvania and Oxford, United Kindgom--(Newsfile Corp. - March 27, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, today announced that The Lancet published the company's pivotal Phase 2 data with afami-cel. The article , titled "SPEARHEAD-1: a single-arm phase 2 trial of afamitresgene autoleucel (afami-cel) in advanced synovial... Read More

U.S. FDA accepted BLA for afami-cel for the treatment of advanced synovial sarcoma with priority review and a PDUFA date of August 4 th , 2024 Confirmatory evidence for afami-cel full approval agreed with FDA; will use data from Cohort 2 of pivotal SPEARHEAD-1 trial, which is fully enrolled Company is targeting launch of afami-cel upon receipt of FDA approval with commercial, manufacturing, and supply chain teams preparing... Read More

Cintia Piccina returns as Chief Commercial Officer effective March 18, 2024 Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - February 27, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, today announced the reappointment of Cintia Piccina as Chief Commercial Officer effective March 18, 2024. Cintia served in this role... Read More

Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - February 21, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, will report financial results and provide business updates for the fourth quarter and full year ended December 31, 2023, before the US markets open on Wednesday, March 6, 2024. Following the announcement, the... Read More

If approved, afami-cel will be the first engineered T-cell therapy for solid tumors and the first effective treatment option for synovial sarcoma in more than a decade Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - January 31, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, today announced that the U.S. Food and Drug... Read More

Sarcoma franchise of afami-cel and lete-cel leverages same development and commercial footprint with US peak year sales projected to be up to $400 million BLA submitted in 2023 for afami-cel; projected acceptance by US FDA in Q1 2024 Company preparing for US launch of afami-cel in 2H 2024 upon expected approval Pivotal trial for lete-cel met its primary endpoint for efficacy; full data set in Q3 2024 Company working toward... Read More

First BLA for an engineered T-cell therapy for solid tumors submitted to U.S. Food and Drug Administration Afami-cel data demonstrate better outcomes for people with synovial sarcoma compared to historical control data; pivotal trial has met primary endpoint for efficacy Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - December 6, 2023) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell... Read More

Interim analysis of pivotal IGNYTE-ESO trial demonstrates 40% response rate in people with synovial sarcoma or myxoid/ round cell liposarcoma Company will lay out plans for its cell therapy sarcoma franchise including afami-cel and lete-cel in January 2024 Philadelphia, Pennsylvania. and Oxford, United Kingdom--(Newsfile Corp. - November 29, 2023) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to... Read More

Afami-cel: overall survival for people with synovial sarcoma who received afami-cel is superior to historic controls ( CTOS 2023 ); BLA submission on track to complete in Q4 this year SURPASS Phase 1 trial: 75% response rate in ovarian, urothelial, and head & neck cancers in patients with ≤ 3 prior lines of therapy ( ESMO 2023 ) SURPASS trial plans: Phase 1 trial focused on head & neck and bladder cancers in earlier line... Read More

Candidate is 10x more sensitive to target peptide than competitor candidates Entry into the clinic in 2024 Selection of approaches from next-gen toolbox in development Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - November 8, 2023) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, provides a progress update on its PRAME program (ADP-600). Jo Brewer Adaptimmune... Read More

~39% of patients who received afami-cel in the pivotal SPEARHEAD-1 trial had clinical responses with a median duration of response of ~12 months ( CTOS 2022 ) Median overall survival (mOS) was ~17 months in SPEARHEAD-1 compared to historical mOS of <12 months for people with synovial sarcoma who received two or more prior lines of therapy [1] 70% of people with advanced synovial sarcoma who respond to afami-cel are alive two... Read More

40% (18/45) of people with synovial sarcoma or MRCLS and who have received ≥ 2 prior lines of therapy had clinical responses with lete-cel, by independent review [2] ; primary efficacy endpoint requires 16/60 patients have responses Median duration of response was ~11 months, data are immature and still evolving 80% (4/5)... Read More

Philadelphia, Pennsylvania and Oxfordshire, United Kingdom--(Newsfile Corp. - October 25, 2023) - Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in cell therapy to treat cancer, will report financial results and provide business updates for the third quarter ended September 30, 2023, before the US markets open on Wednesday, November 8, 2023. Following the announcement, the Company will host a live teleconference and... Read More

35% response rate in the ADP-A2M4CD8 monotherapy cohort with ~5 months median duration of response in heavily pre-treated patients across a broad range of solid tumors 50% response rate in 26 patients with ovarian, urothelial, and head & neck cancers 75% response rate in ovarian, urothelial, and head & neck cancers in patients... Read More

Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - September 11, 2023) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, today announces that Karen Chagin, MD has joined the Company as its Senior Vice President of Early-Stage Development. Dr. Chagin will oversee the Company's early-stage pipeline activities from pre-IND and IND activities through Phase 1 clinical... Read More

Substantial progress on the afami-cel BLA including FDA agreement on plan for confirmatory evidence and favorable feedback on commercial T-cell potency assay - submission now targeted for Q4 2023 Transition of lete-cel from GSK and data from the completed pivotal trial in synovial sarcoma and MRCLS expected in late 2023... Read More

Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - August 3, 2023) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, will report financial results and provide business updates for the second quarter ended June 30, 2023, before the US markets open on Wednesday, August 9, 2023. Following the announcement, the Company will host a live conference call at 8:00 a.m. EDT... Read More

First marketed engineered T-cell therapy for a solid tumor; BLA for afami-cel on track to complete submission in mid-2023 Compelling clinical data with late-stage programs targeting MAGE-A4 and mesothelin Preclinical programs targeting PRAME and CD70 in IND-enabling studies Adaptimmune funded into early 2026 with multiple... Read More

Approximately 39% of patients had clinical responses after a single dose of afami-cel in Cohort 1 of the pivotal SPEARHEAD-1 trial and the median duration of response was ~12 months (CTOS 2022) Median overall survival (mOS) was ~17 months Patients with a RECIST response have a 12-month OS probability of 90% and 24-month OS probability of 70%, and the mOS for responders has not yet been reached Historical outcomes are poor... Read More

Completed submission of the clinical module (Part 2) of the afami-cel BLA; afami-cel is targeted to be the first marketed engineered T-cell therapy for a solid tumor Adaptimmune and GSK agreed terms for transfer of PRAME and NY-ESO target programs; Adaptimmune will receive ~$37 million in upfront and milestone payments Announced strategic combination with TCR 2 to create a preeminent cell therapy company for solid tumors;... Read More

Philadelphia, Pennsylvania and Oxfordshire, United Kingdom--(Newsfile Corp. - April 28, 2023) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, will report financial results and provide business updates for the first quarter ended March 31, 2023, before the US markets open on Friday, May 12, 2023. Following the announcement, the Company will host a live teleconference and webcast at... Read More

Adaptimmune plans to be IND-ready in 2023 with a PRAME targeted TCR T-cell therapy Adaptimmune and GSK will work collaboratively to ensure continuity for patients in ongoing clinical trials for lete-cel and next generation TCR T-cells targeting NY-ESO Adaptimmune will receive £30 million in relation to the transition of the ongoing NY-ESO clinical trials Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp.... Read More

BLA submission initiated for afami-cel, with aim to complete in mid-2023; afami-cel has the potential to be the first marketed engineered TCR T-cell therapy for a solid tumor 52% (13/25) response rate in ovarian, bladder and head & neck cancers in the Phase 1 SURPASS trial with next-generation MAGE-A4 product; 75% (9/12) response rate amongst patients with these tumor types who received ≤ 3 prior lines of therapy Adaptimmune... Read More

Compelling clinical data with clear paths to products and multiple near‐term value-creating catalysts Complementary technology platforms designed to treat solid tumors which represents a substantial market opportunity largely unaddressed by cell therapies Following closing of the transaction, cash runway extended into 2026... Read More

Philadelphia, Pennsylvania and Oxfordshire, United Kingdom--(Newsfile Corp. - February 22, 2023) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, will report financial results and provide business updates for the fourth quarter and full year ended December 31, 2022, before the US markets open on Monday, March 6, 2023. Following the announcement, the Company will host a live webcast at... Read More

Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - February 16, 2023) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in T-cell therapy to treat cancer, today announced that Kristen M. Hege, M.D. will join its board of directors. In addition, Dr. Tal Zaks, who has served as a Non-Executive Director since 2016, will be stepping down from the board of directors. "On behalf of the Board and... Read More

The response rate was 44% in patients with late-stage, metastatic synovial sarcoma after a single dose of afami-cel Based on these results, the Company initiated a Phase 2 trial with afami-cel for people with sarcoma, SPEARHEAD-1, and these data are being used to support a rolling BLA submission for approval Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - January 9, 2023) - Adaptimmune Therapeutics... Read More

Afami-cel has the potential to be the first approved engineered TCR T-cell therapy for a solid tumor ynovial sarcoma has a high unmet medical need and the pivotal trial met its primary endpoint with an overall response rate of ~39% after a single dose of afami-cel Adaptimmune plans to complete its rolling BLA submission for afami-cel in mid-2023; and with RMAT status for synovial sarcoma, the application will be eligible for... Read More